Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
556 stopped studies mapped to Acute Myeloid Leukemia and descendants · 90% state a reason
Over the 556 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00101140 | Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission | Phase 2 | withdrawn | Jan 10, 2005 | Eastern Cooperative Oncology Group | not stated | Not stated |
| NCT03138395 | iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML(iCare3) | — | withdrawn | May 3, 2017 | University of Florida | Study design modified to collect specimens from a bank requiring a separate IRB-approved protocol. | Other (stated, no rule matched) |
| NCT02255162 | Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML | Phase 1 | terminated | Oct 2, 2014 | Massachusetts General Hospital | Slow Accrual | Enrollment / accrual |
| NCT01034592 | Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent… | Phase 1 | terminated | Dec 17, 2009 | Jason Robert Gotlib | Poor accrual related to rarity of Diamond-Blackfan anemia (DBA) | Enrollment / accrual |
| NCT01342887 | Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating… | Phase 1 / Phase 2 | terminated | Apr 27, 2011 | Fred Hutchinson Cancer Center | not stated | Not stated |
| NCT01076270 | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A… | N/A | terminated | Feb 26, 2010 | Fred Hutchinson Cancer Center | Funding withdrawal | Funding |
| NCT02276651 | Observational Trial of a Therapeutic Platelet Transfusion Regimen | — | terminated | Oct 28, 2014 | Klinikum Nürnberg | Insufficient recruitment | Enrollment / accrual |
| NCT00673153 | Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated… | Phase 2 | terminated | May 7, 2008 | Fred Hutchinson Cancer Center | not stated | Not stated |
| NCT02259348 | Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following… | Phase 2 | terminated | Oct 8, 2014 | St. Jude Children's Research Hospital | Investigator's decision. | Investigator |
| NCT00863434 | Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal… | Phase 2 | terminated | Mar 18, 2009 | University of Washington | not stated | Not stated |
| NCT01483274 | Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem…(AML) | Phase 1 | withdrawn | Dec 1, 2011 | University of Louisville | Adult patient population barriers. | Other (stated, no rule matched) |
| NCT02791919 | Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children,… | Phase 1 | withdrawn | Jun 7, 2016 | National Cancer Institute (NCI) | Other - Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT02520102 | Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction… | Phase 2 | withdrawn | Aug 11, 2015 | Sanofi | Company has fulfilled post-marketing requirements | Sponsor / business decision |
| NCT02200380 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell… | Phase 2 | terminated | Jul 25, 2014 | Celldex Therapeutics | not stated | Not stated |
| NCT01465386 | Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission | Phase 2 | terminated | Nov 4, 2011 | Fred Hutchinson Cancer Center | Closed early due to slow enrollment | Enrollment / accrual |
| NCT01607645 | Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or… | Phase 2 | terminated | May 30, 2012 | Fred Hutchinson Cancer Center | The study was terminated early because there were other competing protocols. | Other (stated, no rule matched) |
| NCT00363467 | Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell… | N/A | terminated | Aug 15, 2006 | H. Lee Moffitt Cancer Center and Research Institute | Low accrual | Enrollment / accrual |
| NCT01749111 | Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin…(CICLODECH) | Phase 3 | terminated | Dec 13, 2012 | Hospital Israelita Albert Einstein | Lack of accrual | Enrollment / accrual |
| NCT01621477 | T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell… | Phase 2 | terminated | Jun 18, 2012 | St. Jude Children's Research Hospital | Study was terminated in August 2016 due to replacement by a new study. | Other (stated, no rule matched) |
| NCT01843179 | Sulindac for Patients With AML | Phase 2 | withdrawn | Apr 30, 2013 | Massachusetts General Hospital | Lack of Funding | Funding |
| NCT00052598 | Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or… | Phase 1 / Phase 2 | terminated | Jan 27, 2003 | Fred Hutchinson Cancer Center | not stated | Not stated |
| NCT01176422 | Telomere and Telomerase | — | withdrawn | Aug 6, 2010 | University of Kansas Medical Center | lack of resources; no patient enrollment | Enrollment / accrual |
| NCT01520805 | Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and… | Phase 2 | withdrawn | Jan 30, 2012 | Cornerstone Pharmaceuticals | not stated | Not stated |
| NCT02528877 | Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host… | Phase 1 | withdrawn | Aug 19, 2015 | City of Hope Medical Center | The study design was revised so a new protocol will be opened. | Other (stated, no rule matched) |
| NCT02303782 | A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in… | Phase 1 / Phase 2 | withdrawn | Dec 1, 2014 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | not stated | Not stated |
| NCT01960387 | Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia(UPCI 13-066) | Phase 2 | terminated | Oct 10, 2013 | University of Pittsburgh | lack of accrual | Enrollment / accrual |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With… | Phase 2 | withdrawn | Jul 27, 2012 | University of Medicine and Dentistry of New Jersey | Funding unavailable | Funding |
| NCT00185523 | Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous… | — | terminated | Sep 16, 2005 | Stanford University | not stated | Not stated |
| NCT02029417 | Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With… | Phase 2 | terminated | Jan 7, 2014 | Roswell Park Cancer Institute | Major revisions needed in study | Other (stated, no rule matched) |
| NCT00579111 | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | Phase 1 / Phase 2 | terminated | Dec 21, 2007 | Baylor College of Medicine | slow accrual | Enrollment / accrual |
| NCT02221505 | Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute… | Phase 1 | terminated | Aug 20, 2014 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT01573247 | Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia | Phase 1 / Phase 2 | terminated | Apr 9, 2012 | Akinion Pharmaceuticals AB | During the study two patients have experienced serious liver events related to AKN-028. The… | Other (stated, no rule matched) |
| NCT01455025 | Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute…(PRIMAL) | Phase 1 | terminated | Oct 19, 2011 | French Innovative Leukemia Organisation | no recruitment on time | Enrollment / accrual |
| NCT00664677 | Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia | Phase 1 | terminated | Apr 23, 2008 | Erimos Pharmaceuticals | Funding constraints | Funding |
| NCT00660036 | Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid… | Phase 1 | terminated | Apr 17, 2008 | University of Pittsburgh | due to new safety information | Safety / toxicity |
| NCT01067274 | ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)(ALFA-0703) | Phase 3 | withdrawn | Feb 11, 2010 | Acute Leukemia French Association | Study abandoned | Other (stated, no rule matched) |
| NCT00866281 | A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed… | Phase 1 / Phase 2 | terminated | Mar 20, 2009 | Novartis Pharmaceuticals | Despite considerable efforts to boost recruitment during the final year of the study, no new… | Enrollment / accrual |
| NCT02034227 | Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic… | Phase 1 / Phase 2 | terminated | Jan 13, 2014 | Spirogen | not stated | Not stated |
| NCT00670150 | New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic… | Phase 2 | withdrawn | May 1, 2008 | University of Southern California | sponsor withdrew support | Other (stated, no rule matched) |
| NCT01794169 | Azacitidine Compared to Conventional Chemotherapy as Consolidation of Elderly Patients… | Phase 2 | terminated | Feb 18, 2013 | Karolinska University Hospital | Poor recruitment | Enrollment / accrual |
| NCT01260714 | Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With… | Phase 1 | terminated | Dec 15, 2010 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT01489722 | Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous… | Phase 1 | terminated | Dec 12, 2011 | AstraZeneca | not stated | Not stated |
| NCT01908387 | Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms | Phase 1 | terminated | Jul 25, 2013 | Celgene Corporation | Due to Slow Accrual study was terminated. | Enrollment / accrual |
| NCT00374296 | MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With… | Phase 2 | terminated | Sep 11, 2006 | Mirati Therapeutics Inc. | The Clinical Development Program for MGCD0103 is being re-evaluated | Other (stated, no rule matched) |
| NCT00963495 | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients… | Phase 1 | terminated | Aug 21, 2009 | University Health Network, Toronto | not stated | Not stated |
| NCT01222143 | Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and… | Phase 1 / Phase 2 | terminated | Oct 18, 2010 | University Health Network, Toronto | not stated | Not stated |
| NCT01521936 | Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive… | Phase 2 | terminated | Jan 31, 2012 | Roswell Park Cancer Institute | Lack of funding | Funding |
| NCT00666497 | Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With… | Phase 2 | terminated | Apr 25, 2008 | Mirati Therapeutics Inc. | Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103. All… | Other (stated, no rule matched) |
| NCT00669890 | Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML(High Risk) | Phase 1 | terminated | May 1, 2008 | New York Medical College | PI left institution | Investigator |
| NCT00943553 | A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction… | Phase 2 | withdrawn | Jul 22, 2009 | Eisai Inc. | Terminated by Sponsor | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Oct 19, 2017source: clinicaltrials